Geron Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3741631036
USD
1.57
0.03 (1.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
ANI Pharmaceuticals, Inc.
Aurinia Pharmaceuticals, Inc.
Vir Biotechnology, Inc.
Rhythm Pharmaceuticals, Inc.
Twist Bioscience Corp.
Geron Corp.
Iovance Biotherapeutics, Inc.
Xencor, Inc.
Summit Therapeutics, Inc.
Spyre Therapeutics, Inc.
Disc Medicine, Inc.

Why is Geron Corp. ?

1
With a growth in Net Profit of 69%, the company declared Very Positive results in Sep 25
  • The company has declared positive results for the last 3 consecutive quarters
  • NET SALES(HY) At USD 96.26 MM has Grown at 230.2%
  • OPERATING CASH FLOW(Y) Highest at USD -132.92 MM
  • NET PROFIT(HY) Higher at USD -34.8 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -13.71%, its profits have risen by 61.1%
3
Reducing Promoter Confidence
  • Promoters have decreased their stake in the company by -1.28% over the previous quarter and currently hold 11.32% of the company
  • Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 13.68% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -13.71% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Geron Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Geron Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Geron Corp.
-10.29%
-1.04
67.30%
S&P 500
13.68%
0.71
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
183.78%
EBIT Growth (5y)
4.49%
EBIT to Interest (avg)
-31.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.25
EV to EBIT
-14.65
EV to EBITDA
-14.94
EV to Capital Employed
7.97
EV to Sales
5.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-54.44%
ROE (Latest)
-31.48%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company
NET SALES(HY)

At USD 96.26 MM has Grown at 230.2%

OPERATING CASH FLOW(Y)

Highest at USD -132.92 MM

NET PROFIT(HY)

Higher at USD -34.8 MM

ROCE(HY)

Highest at -29.57%

RAW MATERIAL COST(Y)

Fallen by 0.57% (YoY

CASH AND EQV(HY)

Highest at USD 772.26 MM

-11What is not working for the Company
INTEREST(HY)

At USD 17.16 MM has Grown at 169.6%

DEBT-EQUITY RATIO (HY)

Highest at -52.74 %

Here's what is working for Geron Corp.

Net Sales
At USD 96.26 MM has Grown at 230.2%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Net Profit
Higher at USD -34.8 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Profit
At USD -34.8 MM has Grown at 62.91%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Operating Cash Flow
Highest at USD -132.92 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv
Highest at USD 772.26 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by 0.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Geron Corp.

Interest
At USD 17.16 MM has Grown at 169.6%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio
Highest at -52.74 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio